Challenges and Strategies in the Development of Anti-Cancer Nanomedicine

16 October 2024 | 11:15 - 12:45

Nanomedicine has been poised to provide improved cancer therapies, yet the translation from laboratory to clinic has had limited success despite the tremendous research efforts. Challenges in the field impeding translational progress, include the biocompatibility and targeting efficacy of nanocarriers, physiological barriers to delivery, scalability of production, and the regulatory landscape shaping the development process. To overcome these challenges, this session aims to cover strategies to surmount these hurdles, including advancements in nanoparticle engineering, precision targeting mechanisms, and adaptive clinical trial designs. These strategies are a necessary step to address the multifaceted challenges in the successful development of anticancer nanomedicine, thus bridging the gap between bench and bedside.